Эффективность дистанционной ударно-волновой терапии при болезни Пейрони
Диссертация
При денситометрической плотности бляшек менее 110 Ед. и их толщине не более 2,5 мм целесообразно использование аппаратов с генерацией ударной волны, воздействующей на патологический субстрат с перифериипри денситометрической плотности бляшек более 140 Ед. и их толщине, превышающей 2,5 мм наибольшим клиническим эффектом обладают аппараты, обеспечивающие генерацию энергии в центр субстрата. Средние… Читать ещё >
Список литературы
- Аляев Ю.Г., Рапопорт Л. М., Винаров А. З., Попко А. С., Григорьев Н. А. Комбинированная консервативная терапия болезни Пейрони. Врачебное сословие № 2 2003.
- Аляев Ю.Г., Рапопорт JI.M., Щеплёв П. А., Винаров А. З., Попко А. С., Чибисов М. П. Комбинированная терапия фибропластической индурации полового члена.Андрология и генитальная хирургия № 2 2003.
- Зубарев А.В., Гажонова В. Е. Диагностический ультразвук Уронефрология. Практическое руководство. Москва, 2002,248с.
- Зубарев А.Р., Митькова М. Д., Корякин М. В. Ультразвуковая диагностика заболеваний наружных половых органов у мужчин. Москва, Ви-дар, 1999,99с.
- Лопаткин Н.А., Дмитриев Д. Г. Болезнь Пейрони. Руководство по урологии 3-х томник. Москва 1998 г.
- Мазо В.Е. Консервативная терапия фибропластической индурации полового члена-болезни Пейрони. Урология и нефрология № 3 1984.
- Мазо Е.Б., Зубарев А. Р., Жуков О. Б. Ультразвуковая диагностика васкуло-генной эректильной дисфункции.Москва, Медицина, 2003,112с.
- Abdel-Salam Y, Budair Z, Renner C. Treatment of Peyronie’s disease by extracorporeal Shockwave therapy: Evaluation of our preliminary results. J En-dourol 1999−13:549−552.
- Ahuja S et al. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie’s disease. J Androl 1999−20:444−448.
- Akkus E, Carrier S, Renman J, Breza J, Kadioglu A, Lue T. In colchicines effective in Peyronie’s disease? A pilot study. Urology 1994−44(2):291−5.
- Andersen R, Wegner H, Banzer D, Miller K. Ultrasound and sofit-tissue radiography to monitor local interferon-alfa 2b treatment in Peyronie’s disease. Acta Radiol 1996−37(3):352−6.
- Andersen R, Wegner H, Miller K, Banzer D. Imaging modalities in Peuronie’s disease. Eur Urol 1998−34:128−35.
- Arena F. Clinical effects of verapamil in the treatment of Peyronie’s disease. Acta Biomed Ateneo Parmense 1995−66:269−272.
- Balconi G, Angeli E, Nessi R, de Flavis L. Ultrasonographic evaluation of Peyronie’s disease. Urol Radiol 1988−10:85−8.
- Bellorofonte C, Ruoppolo M, Tura M, Zaatar C, Tombolini P, Menchini Fabris GF. Possibillitty of using the piezoelectric lithotriptor in the treatment of severe cavernous fibrosis. Arch Ital Urol Nefrol Androl 1989−61(4):417−22.
- Benson R, Knoll L, Furlow W. Interferon-alfa 2b in the treatment of Peyronie’s disease. J Urol 1991- 145(suppl):1342A.
- Border WA, Noble NA. Transforming growth factor-beta in tissue fibrosis. N Engl J Med 1994- 331(19):1286−92.
- Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992−90(l):l-7.
- Brake M, Loertzer H, Horsch R, Keller H. Treatment of Peyronie’s disease with local interferon-alfa 2b.
- Brock G, Kadioglu A, Lue TF. Peyronie’s disease: a modified treatment. Urology 1993−42(3):300−4.
- Butz M. Treatment of Peyronie’s disease by extracorporeal shock waves. J Endourol 1995−9: 165−8.
- Bystrom J, Rubio C. Induration Penis Plastica: Clinical features and etiology. Scand J Urol Nephrol 1976−10:12−20.
- Carrieri MP, Serraino D, Palmiotto F, Nucci G, Sasso F. A case-control study on risk factors for Peyronie’s disease. J Clin Epidemiol 1998:51(6):511−5.
- Colletta A, Wakefield L, Howell F. Anioestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. British journal Cancer 1990(62):405−9.
- Crowne D, Marlow D. A new scale of social desirability independent of psychopathology. J Consult Clin Psychol 1960-(24):349−354.
- Davis CJ. The microscopic pathology of Peyronie’disease. Jornal of Urology 1997-(l):282−4.
- Desai KM, Gingell JC. Out-patient assessment of penile curvature. Br J Urol 1987−60(5):470−1.
- Devine CJ, Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie s lesion. J Urol 1997- 157(l):285−90.
- Devine CJ, Horton CE. Peyronie's disease. Clin Plast Surg 1988−15(3):405−9.
- Devine CJ, Jr. International Conference on Peyronie’s disease advances in basic and clinical research. March 17−19, 1993.Introduction. J Uroll997−157(l):272−5.
- Diegelmann RF. Cellular and adnormal wound healing: an overview. J Urol 1997−157(l):298−302.
- Duncan M, Berman B, Nseyo U. Regulation of proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasta by interferons-alfa,-beta and -gamma. Scan. J Urol Nephrol 1991 -25:89−94.
- El-Sakka AI et al. An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997−158:2284−2290.
- Erdogru T, Boz A, Koksal T, Usta M, Yildiz A, Gungor F, Baykara M. Penile scintigraphy with 99m Tc-human immunoglobulin G: a novel method for distinguishing the unstable and stable phases of Peyronie’s disease. BJU2002−90:703−706.
- Felipetto R, Vigano L, Pagni G, Minervini R. Laser and ultrasonic therapy in simultaneous emission for the treatment of plastic penile induration. Minerva Urol Nefrol 1995−47(l):25−9.
- Frank I, Scott W. The ultrasonic treatment of Peyronie’s disease. J Urol 1971−106(6):83−7.
- Gasior B, Levine F, Howannesian A, Krane R, Goldstein I. Plaque-associated corporal veno-occlussive dysfunction idiopapathetic Peyronie’s disease: a pharmacavernosomatic and pharmacocavernosographic study. World J Urol 1990−8:90−6.
- Gelbard M. Peyronie's Disease. In: Hashmat Al, Das S, editors. The Penis. Philadelphia: Lea and Febiger- 1993.p.244−65.
- Gelbard MK. Controlled vacuum chamber for standardized photographic documentation of penile erectile deformity. Urology 1990-(36):367−369.
- Gerald H, Ulrich S, Behnam F, Ubo E. Radial shock wave therapy: a new option for Peyronie’s disease. Radiology 2002−4:46−8.
- Gerbard M, Dorey F, James K. The natural history of Peyronie’s disease. J Urol. 1990(144): 1376−9.
- Gholami SS, Lue TF. Peyronie’s disease. Urol Clin N Am 2001-(28):377−390.
- Gonzalez-Cadavid NF, Magee TR, Ferrini M, Qian A, Vernet D, Raifer J. Gene expression in Peyronie’s disease. 2002-(14):361−374.
- Hakim LS. Peyronie’s disease: an update The role of diagnostics. Int J Res Imp 2002-(12):321−323.
- Hamm B, Friendrich M, Kelami A. Ultrasound imaging in Peyronie’s disease. Urology 1986−28(6):540−5.
- Harris E, Krane S. Effect of colchicines on collagenase in culture of rheumatoid synovium. Arthitis Rheum 1971 — 14:669−84.
- Hasche-Klunder R. Treatment of Peyronie’s disease with para-aminobenzoacidic potassium (Potaba). Urology 1978−17(4):224−7.
- Hauck E, Altinkilic B, Ludwig M, Ludecke G, Schroeder-Printzen I, Arens C, Weidner W. Extracorporal shock wave therapy in the treatment of Peyronie’s disease. Eur Urol 2000−38:663−670.
- Haupt G: Use of extracorporal shock waves in the treatment of the psendarthrosis, tendinopathy and other ortopedic disease. J Urol 1997−158:4−22.
- Hellstromm WLG. History, epidemiology, and clinical presentation of Peyronie’s disease. Int J Imp Res 2003-(15) suppl 5:91−92.
- Helweg G, Judmaier W, Wicke K, Oberhauser A, zur Nedden D, Ennemoser O. Ultrasound and MRI in the diagnosis of penile induration (Peyronie's disease).Eur Radiol 1992−2:230−2.
- Hricak H, Marotti M, Gilbert T, Lue T, Wetzel L, McAninch J. Normal penile anatomy and adnormal penile condition with MR imaging. Radiology 1988−169:683−90.
- Husain J, Lynn N, Jones D, Collins G, O’Reilly P. Extracorporeal shock wave therapy in the management of Peyronie’s disease: initial experience. Br J Urol 86-(4):466−68.
- Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie s disease and erectile dysfunction. J Urol 1997- 158 (4): 1388−90.
- Jones WJ. Couseling men with sexual dysfunction. AUA Update Series 1977.
- Jordan GH, Angermeier KW. Preoperative evaluation of erectile function with dynamic cavernsometry/cavernosography in patients undergoing surgery for Peyronie’s disease. Survey of 50 patients. J. Urol 1993(150): 1138.
- Kelami A. Classification of congenital and acquired penile deviation. Urol Int 1983 -3 8(4):229−3 3.
- La Pera G, Pescatori E, Calabrese M, Boffini M, Colombo F, Andriani E, Natali A, Vaggi L, Catuogno C, Giustini M, Taggi F and SIMONA Study Group. Peyronie’s Disease: Prevalence and association with cigarette smoking. Eur Urol 2001-(40):525−530.
- Lebret T, Herve J, Lugagne P, Barre P, Orsini J, Butreau M, Botto H. Extracorporeal lithotripsy in the treatment of Peyronie’s disease: Use of standard lithotriptor (Multiline Siemens) on «young"(less than 6 month old) plaques. Prog Urol 2000- 10.
- Leffell MS. Is there an immunogenetic basic for Peyronie’s disease? Journal of Urology 1997- 157(1): 195−7.
- Levine L, Coogan C. Penile vascular assessment using color duplex sonography. J Urol 1996−155:1720.
- Levine L, Lenting E. A surgical algorithm for the treatment of Peyronie’s disease. J Urol 1997−158:2149−2152.
- Levine L, Merrick P, Lee R. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol 1994−151:1522−1524.
- Levine LA, Greenfield JM. Establishing a standardized evaluation of the man with Peyronie’s disease. Int J Impot Res 2003−15suppl 5: 103−112.
- Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie s disease in Rochester, Minnesota, 1950 through 1984. J ui’ol 1991- 146 (4)-1007−9.
- Locke W. Short material adjustment and prediction tests: their reliability and validity. J Marriage Fam 1959-(21):251−255.
- Lopez J, Jarow J. Dupplex ultrasound findings in the men with Peyronie’s disease. Urol Radiol 1991- 12:199 202.
- Lopez JA, Jarow JP. Penile vascular evaluation of men with Peyronie’s disease.
- Lue T, Gueglio G, Jordan G, Levine L, Moreland R, Pryor J, Ralph D, Yachia D. Peyronie’s disease. 1st International Consultation on Erectile Dysfunction-July 1−3, 1999, Paris.
- Lue TF. Peyronie's disease: an anatomically-based hypothesis and beyond. Int J Impot Res 2002-(14):411−413.
- Lyles KW, Gold DT, Newton RA, Parekh S, Shipp KM, Pieper CF, et al. Peyronie’s disease is associated with Paget’s disease of bone. Journal of Bone and Mineral Research 1997−12(6):929−34.
- Metz P, Ebbehoj J, Uhrenholdt A, Wagner G. Peyronie’s disease and erectile failure. J Urology 1983- 139(6):1103−4.
- Michel M, Ptaschnyk T, Musal A, Braun P, Lenz S, Alken P, Kohrmann K. Objective and subjective changes in patients with Peyronie’s disease after management with schockwave therapy. J Endourol 2003−17:41−44.
- Montorsi F, Guazzoni G, Bergamaschi F, Consonni P, Rigatti P, Pizzini G, et al. Vascular adnormalities in Peyronie’s disease: the role of color Doppler sonography. J Urol 1994−151(2):373−5.
- Moreland RB, Nehra A. Pathophysiology of Peyronie’s disease. Int J Impot Res 2002-(14):406−410.
- Morgan R, Pryor J. Procarbazine (Natulan) in the treatment of Peyronie’s disease. British J Urol. l978−50:l 11−3.
- Mynderse L, Monga M. Oral therapy for Peyronie’s disease. Int J Imp Res 2002−14:340−344.
- Noss MB, Day NS, Christ GJ, Melman A. The genetics and immunology of Peyronie’s disease. Int J Impot Res 2000-(12): 127−132.
- Oosterlinck W, Renders G. Treatment of Peyronie’s disease with procarbazine. Br J Urol 1975−47(2):219−20.
- Peyronie. Andrologie 1998−8: 148−56.
- Polkey HJ. Induration penis plastica. Urol Cut Rew 1928−32:287−308.
- Pryor J, Farrell C. Controlled clinical trial of vitamin E in Peyronie’s disease. Prog Reprod Bio Med 1983- 9- 41−42.
- Pryor JP, Ralh DJ. Clinical presentation of Peyronie’s disease. Int J Impot Res 2002-(14):414−417.
- Ralph D.J., Schwartz G, Moore W, Piyor J P, Ebringer A, Bottazzo GF. The genetic and bacteriological aspects of Peyronie s disease. J Urol 1997 — 157 (l):291−4.
- Ralph DJ, Hughes T, Lees WR, Piyor JP. Preoperative assessment of Peyronie’s disease using colour Doppler sonography. Br J Urol 1992−69(6):62 990?fealph DJ. What’s new in Peyronie’s? Cur Opin Urol 1999-(9):569−571.
- Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term sing-bling study. Urology 1998- 51:620 626.
- Rosen RC et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997-(49):822−830.
- Satragno L, Martionoli C, Cittadini G. Magnetic resonance imaging of the penis: normal anatomy. Magn Reson Imaging 1989−7:95−100.
- Schouman-Claeys E. Valeur et place de l’imagerie de la maladie de la
- Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie’s disease: results of a large survey. Br J Urol 2001-(88):727−730.
- Scott W, Scardino P. A new concept in the treatment of Peyronie’s disease. South Med J 1948−41:173.
- Shabsigh R, Fleming M, Perelman M, Anastasiadis A. Peyronie’s disease index (PDI), a standardized patient questionnaire. Int J Impot Res 2002- 14(suppl 3): 68.
- Shaw K, Puri K, Ruiz-Deya G, Hellstrom WJG. Racial considerations in the evaluation of Peyronie’s disease. J Urol 2001- 165: 170:687A.
- Smith BH. Subclinical Peyronies disease. Am J Clin Pathol 1969−52(4):3 8590.
- Somers KD, Dawson DM. Fibrin deposition in Peyronie’s disease Plaque. J Urol 1997−157(1):311−5.
- Sommer F, Schwarzer U, Wassmer G, Bloch W, Braun M, Klotz T, Engelmann U. Epidemiology of Peyronie’s disease. Int J Impot Res 2002-(14):379−383
- Stecker J, Divine C. Evaluation of erectile dysfunction in patients with Peyronie’s Disease. J Urol 1984−132:680−1.
- Tefekli A, Kandirali E, Erol H, Alp T, Koksal T, Kadioglu I. Peyronie’s disease in men under 40: characteristics and ontcome. Int J Imp Res 2001-(13):18−23.
- Treffiletti S, Annoscia S, Montefiore F, Boccafoschi C. Iontophoresis in the conservative treatment of Peyronie’s disease: preliminary experience. Arch Ital Urol Androl 1997−69(5):323−7.
- Vosshenrich R, Schroeder-Printzer I, Weidner W, Fischer U, Funke M, Ringert R. Value of magnetic resonance imaging in patiens with penile induration (Peyronie's disease). J Urol 1995−153:1122−5.
- Wahl S, Mccartney-francis N, Mergenhagen S. Inflammatory and immunomodulatory roles of TBF-b.Immunol Today 1989(10):258−61.
- Williams G, Green N. The non-surgical treatment of Peyronie’s disease. Br J Urol 1980−52(5):392−5.
- Winter C, Khanna R. Peyronie’s disease: results with dermojet injection of dexamethasone. J Urol 1975−14:989−00.
- Zarafonatis C, Horrax T. Treatment of Peyronie’s disease with Potaba. J Urol. 1953 (81):770−2.